Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma
Completed · Phase 1/Phase 2
Conditions studied: Leukemia, Lymphoma
In brief
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Interleukin-2 may stimulate a person's white blood cells to kill leukemia or lymphoma cells. Combining these two therapies may be an effective treatment for leukemia and lymphoma. PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy plus interleukin-2 in treating patients who have leukemia or lymphoma.
Key facts
- Study ID
- NCT00002681
- Run by
- Roger Williams Medical Center
- People needed
- 25
- Starts
- 1995-07-01
- Expected to finish
- 2003-12-01
- Last updated by the study team
- 2011-06-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.